Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5932747 | 0.89 | MEN1 (0.48) | MEN1KMT2AALDH1A1KDM4ECYP2C9 | |
| SCHEMBL27650384 | 0.86 | TSHR (0.46) | MEN1KMT2AALDH1A1TSHRCYP2C9 | |
| SCHEMBL17431030 | 0.84 | TSHR (0.56) | MEN1KMT2AALDH1A1TSHRCYP2C19 | |
| SCHEMBL7367901 | 0.82 | MEN1 (0.42) | MEN1KMT2AALDH1A1TSHRKDM4E | |
| SCHEMBL8223163 | 0.82 | ALDH1A1 (0.33) | MEN1KMT2AALDH1A1TSHRPAOX | |
| SCHEMBL26274264 | 0.80 | MEN1 (0.40) | MEN1KMT2AALDH1A1KDM4ECYP2C9 | |
| SCHEMBL24837512 | 0.79 | MEN1 (0.36) | MEN1KMT2AALDH1A1 | |
| SCHEMBL4124680 | 0.78 | CYP2C19 (0.56) | MEN1KMT2AALDH1A1TSHRKDM4E | |
| SCHEMBL13995258 | 0.78 | MEN1 (0.39) | MEN1KMT2AALDH1A1KDM4ECYP2C9 | |
| SCHEMBL12790496 | 0.78 | MEN1 (0.39) | MEN1KMT2AALDH1A1KDM4ECYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023143208-A1 | PREPARATION METHOD FOR DRUG LINKER CONJUGATE | 苏州宜联生物医药有限公司 | 2023-08-03 | — | — | WO | claimed |
| WO-2023226900-A1 | 2-(PIPERAZINE-2-YL) ACETONITRILE DERIVATIVE, PREPARATION METHOD FOR, AND USE THEREOF | 苏州泽璟生物制药股份有限公司 | 2023-11-30 | — | — | WO | disclosed |
| US-20160009657-A1 | AMINE-CONTAINING LIPIDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-01-14 | — | — | US | disclosed |
| US-9006487-B2 | Amine-containing lipids and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-04-14 | — | — | US | disclosed |
| EP-1255738-B1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2012-03-07 | — | — | EP | disclosed |
| CN-102369181-A | Method for the continuous production of alkylamino acrylamides | EVONIK ROEHM GMBH | 2012-03-07 | — | — | CN | disclosed |
| CN-101027276-B | Method for the continuous production of alkyl amino acryl amides | ROEHM GMBH | 2011-08-17 | — | — | CN | disclosed |
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2011-03-03 | — | — | US | disclosed |
| US-20110009641-A1 | Amine-containing lipids and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | disclosed |
| CN-100569733-C | Method for the continuous production of alkylamino acrylamides | ROEHM GMBH (DE) | 2009-12-16 | — | — | CN | disclosed |
| CN-101027276-A | Method for the continuous production of alkyl amino acryl amides | ROEHM GMBH (DE) | 2007-08-29 | — | — | CN | disclosed |
| CN-1795107-A | Aqueous white pigment compositions | CLARIANT FINANCE BVI LTD (GB) | 2006-06-28 | — | — | CN | disclosed |
| CN-1795167-A | Method for continuously producing alkylamino(meth)acrylamides | ROEHM GMBH (DE) | 2006-06-28 | — | — | CN | disclosed |
| CN-1053472-C | Oligonucleotides derived from the SOD family | HOFFMANN LA ROCHE (CH) | 2000-06-14 | — | — | CN | disclosed |
| US-5618814-A | Trisubstituted pyrimido [5,4-d] pyrimidines for modulating multi-drug resistance and pharmaceutical compositions containing these compounds | DR. KARL THOMAE GMBH (DE) | 1997-04-08 | — | — | US | disclosed |
| CN-1106405-A | Trisubstituted pyrimido [5,4-d] pyrimidines for modulating | THOMAE GMBH DR K (DE) | 1995-08-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | PHOSPHO1, SGMS1, APOB | MEN1 718/4885KMT2A 2906/4885ALDH1A1 2111/4885 |
| US-20110009641-A1 | Amine-containing lipids and uses thereof | PHOSPHO1, CHMP4B, SGMS1 | MEN1 1363/4885KMT2A 2031/4885ALDH1A1 1430/4885 |
| US-20160009657-A1 | AMINE-CONTAINING LIPIDS AND USES THEREOF | PHOSPHO1, CHMP4B, SGMS1 | MEN1 1363/4885KMT2A 2031/4885ALDH1A1 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.